Combined Efficacy of Acamprosate and Disulfiram in the Treatment of Alcoholism: A Controlled Study
Authors:
- 30 May 1998
- journal article
- clinical trial
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 22 (3) , 573-579
Abstract
This study presents the results of a multicenter investigation of the efficacy of acamprosate in the treatment of patients with chronic or episodic alcohol dependence. One hundred eighteen patients were randomly assigned to either placebo or acamprosate, and both groups were stratified for concomitant voluntary use of disulfiram. Treatment lasted for 380 days, with an additional 360‐day follow‐up period. The primary efficacy parameters evaluated were: relapse rate and cumulative abstinence duration (CAD). Results were analyzed according to Intention‐To‐Treat principles using χ2, t, and multiple regression analyses where appropriate. After 30 days on study medication, 40 of 55 (73%) acamprosate‐treated patients were abstinent, compared with 26 of 55 (43%) placebo‐treated patients (p= 0.019). The treatment advantage remained throughout the study medication period and was statistically significant until day 270 (p= 0.028). Twenty‐seven percent of patients on acamprosate and 53% of patients on placebo had a first drink within the first 30 days of the study. The mean CAD was 137 days (40% abstinent days) for the patients treated with acamprosate and 75 days (21% abstinent days) for the placebo group (p= 0.013). No adverse interaction between acamprosate and disulfiram occurred, and the subgroup who received both medications had a better outcome on CAD than the those on only one or no medication. Acamprosate was well tolerated. Diarrhea was the only significant treatment‐induced effect. It was concluded that acamprosate was a useful and safe pharmacotherapy in the long‐term treatment of alcoholism. Concomitant administration of disulfiram improved the effectiveness of acamprosate.Keywords
This publication has 22 references indexed in Scilit:
- International Update: New Findings on Promising MedicationsAlcohol, Clinical and Experimental Research, 1996
- Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptorsEuropean Journal of Pharmacology, 1993
- GABA and Nucleus Accumbens Glutamate Neurotransmission Modulate Ethanol Self‐Administration in RatsaAnnals of the New York Academy of Sciences, 1992
- Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised ratsPharmacology Biochemistry and Behavior, 1992
- Accuracy of the Michigan Alcoholism Screening Test for screening of alcoholism in patients of a medical departmentArchives of internal medicine (1960), 1989
- Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animalsPharmacology Biochemistry and Behavior, 1989
- Lack of effects of Ca-acetyl homotaurinate on chronic and acute toxicities of ethanol in ratsAlcohol, 1987
- Disulfiram treatment of alcoholism. A Veterans Administration cooperative studyJAMA, 1986
- A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved?Pharmacology Biochemistry and Behavior, 1984
- Detecting alcoholism. The CAGE questionnaireJAMA, 1984